Quantum Genomics Corp Widens Net with Acquisition of Eurobiobiz SAS

Drug developer QGC boosts European capacity to identify and select high potential molecules in the lab

JERSEY CITY, N.J. - October 29, 2007 - Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announces today the acquisition of Eurobiobiz SAS, a company specializing in the identification and development of high value-added projects in the field of life sciences and academic research. Financial terms were not disclosed.

QGC's core business is the development of new drugs. In order to do this, the company identifies research projects involving innovative compounds with a high potential of reaching the clinic. Eurobiobiz has developed a tried and tested evaluation method for this type of research project and holds a unique position in Europe in this domain. This acquisition means that a dedicated and experienced team now joins QGC. QGC has already worked with this team for more than a year on the evaluation of a number of scientific projects. Bringing the two companies together will further improve this synergy.

"Through this acquisition, QGC boosts its business development and its ability to detect useful molecules, especially in Eastern Europe where Eurobiobiz has particularly good connections and where scientific resources are under-exploited," said Lionel Ségard, chairman and CEO of QGC. "Eurobiobiz's experience of both in- and out-licensing as well as its know-how in training scientists Europe-wide, is a real plus for QGC and will enable us to accelerate the development of our molecules from the scientist's bench through to late-stage clinical trials."

"I am delighted that Eurobiobiz is adding to its capabilities by joining QGC," said Michel Lepers, founder and director of Eurobiobiz.
"By combining our know-how, we are creating a unique entity in Europe which will become the privileged partner of biomedical research in Europe, and bring to market innovative molecules developed from academic research."

About Eurobiobiz Eurobiobiz is specialized in the identification and management of high value-added projects in the field of life sciences and academic research. Eurobiobiz has acquired in-depth experience in evaluating companies, technology transfer and training. The company organizes regular "Bio Entrepreneur Boot Camps" in collaboration with the European Commission to encourage the creation of innovative science-based companies.

Since the company was set up in 1999, Eurobiobiz has trained more than 650 scientists across Europe and has been actively involved in the creation and development phases of more than 40 biotechnology companies, including Newron (Italy), Kibow Biotech (USA) and Aptys Pharmaceuticals (France).
For more information go to www.eurobiobiz.com

About Quantum Genomics Corp. QGC is a biotechnology company seeking to develop new therapies in areas where an unmet medical need exists. QGC's focus is on metabolism-related diseases and cardiovascular pathologies. It will co-develop some products with academic teams and will set up strategic alliances and commercial partnerships to cover all areas of research in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It has a European office in France under the leadership of Lionel
Ségard.

For more information go to www.Quantum-Genomics.com
-- --

Katie Ollerenshaw
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
katie@ala.com

Brighton Business Centre  95 Ditchling Road  Brighton BN1 4ST  ENGLAND                         
Tel:   +44 1273 675100     Fax:  +44 1273 675400


55 rue Boissonade  75014 Paris  FRANCE         
Tel:  +33 1 56 54 07 00     Fax:  +33 1 56 54 07 01

contact: Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100 allo@ala.com / neil@ala.com

Posted: October 2007


View comments

Hide
(web4)